The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
US oncology biotech CytomX Therapeutics’ shares were down more than 25% at $1.47 in pre-market trading, after the company revealed that the latest clinical data on its praluzatamab ravtansine did not support further development alone. 7 July 2022
USA-based immuno-oncology company Portage Biotech has signed an agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists. 7 July 2022
Privately-held German biotech Ariceum Therapeutics, which is focused on developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has named Serge Sagodira its chief business officer. 7 July 2022
US development-stage mRNA-technology company Kernal Biologics today announced the completion of a $25 million Series A led by Hummingbird Ventures. 7 July 2022
Cambridge, USA-based gene therapy company Sarepta Therapeutics has released positive data from multiple studies investigating its Duchenne muscular dystrophy (DMD) candidate SRP-9001. 7 July 2022
Shares in Minneapolis-based DiaMedica Therapeutics, a biopharma focused on developing novel treatments for neurological disorders and kidney diseases, were down by a third in pre-market trading on Thursday. 7 July 2022
China-based WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. 7 July 2022
The US Food and Drug Administration revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir) for the treatment of COVID-19, to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid. 7 July 2022
It is an exciting time within the schizophrenia market as numerous monotherapies and adjunctive therapies are being developed to address some of the most important unmet needs observed with current antipsychotic treatments. 7 July 2022
Biotech BeiGene has entered into a worldwide strategic collaboration with InnoRNA, a privately-held LNP-based delivery technology and mRNA drug discovery specialist. 6 July 2022
The US Association for Accessible Medicines’ (AAM) Biosimilars Council has released an update on major developments in the biosimilars sector by executive director Craig Burten. 6 July 2022
German companies Evotec and Boehringer Ingelheim have joined forces with French diagnostics firm bioMérieux to form a joint venture to fight antimicrobial resistance (AMR). 6 July 2022
Privately-held US biotech Skyhawk Therapeutics has announced an exclusive worldwide collaboration agreement with French pharma major Sanofi to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. 6 July 2022
Japanese drugmaker Eisai’s shares gained almost 6% to 6,167 yen after, along with partner Biogen, it announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (BAN2401). 6 July 2022
Norwegian biopharma Nordic Nanovector has provided a disappointing update on PARADIGME, its Phase IIb trial of Betalutin (177Lu lilotomab satetraxetan) in third-line relapsed and anti-CD20 refractory follicular lymphoma. 6 July 2022
Excited by the prospect of renewed regulatory support for amyotrophic lateral sclerosis (ALS) candidate AMX0035, investors bought up shares in Amylyx Pharmaceuticals before the opening bell on Tuesday. 6 July 2022
Trials of a potentially curative remedy for type 1 diabetes (T1D) will continue, after the US Food and Drug Administration lifted a clinical hold on the candidate. 6 July 2022
Shares of Swiss pharma giant Roche edged up 2% to 325.35 francs this morning, after it announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio (mosunetuzumab). 6 July 2022
With rapidly increasing worldwide prevalence, Alzheimer’s disease (AD) has been identified as a major global health threat by the international medical community. 6 July 2022